Clonorchiasis Market Share

Clonorchiasis Market Scenario

The global clonorchiasis market is expected to grow USD 430 Million at a CAGR of 4.20% during forecast period 2030. Clonorchiasis is infection with the liver fluke Clonorchis sinensis caused due to eating undercooked freshwater fish. Fever, chills, epigastric pain, tender hepatomegaly, diarrhea, and mild jaundice are the major symptoms of the diseases. Different types of diagnostic tests are used to diagnose the disease in the patients. Clonorchiasis is a problem in Israel, and the incidence rate is increasing continuously in Europe and Asia Pacific countries. Increasing prevalence of clonorchiasis, poor diet, increasing geriatric population and changing lifestyle have driven the growth of the market. During last two decades, there has been a significant increase in the number of the patient suffering from the clonorchiasis. The patient having gastrointestinal diseases are more likely to suffer from this disease. According to the National Institutes of Health, in 2014, 70 to 80 million people affected by all digestive diseases. Moreover, increasing healthcare expenditure, government support for research & development, and increasing prevalence of gastrointestinal diseases have fuelled the growth of the market. Increasing awareness about health hygiene has also contributed to the growth of the market. However, the high cost of the tests & the treatment may lead to slow the growth of the clonorchiasis market.

Figure 1:- Global Clonorchiasis market share, by causes

Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The global clonorchiasis market is segmented on the basis of parasites, therapy, and end users.

On the basis of parasites, the market is segmented into Clonorchis sinensis, Opisthorchis viverrini, Opisthorchis felineus, and others.

On the basis of therapy, the market is segmented into diagnosis and treatment. Diagnosis is further segmented into the microscopic examination, X-ray, serologic tests, and others. Treatment is sub-segmented into praziquantel, cool, cystic, biltricide, and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.

Regional Analysis

America dominates the global clonorchiasis market owing to a well-developed healthcare sector and huge geriatric population. Apart from this, increasing number of patients, poor diet and increasing prevalence of patients suffering from GI diseases have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention in 2014, over 14.8 million of the U.S. people had GI diseases. Additionally, increasing geriatric population, rising healthcare expenditure and increasing awareness among the people regarding health have also contributed to the growth of the market.

Europe accounts for the second largest clonorchiasis market, which is followed by Asia Pacific. Availability of funds for research, substantial patient population, and strong government support for research & development have driven the market growth. During last decade, there is a significant increase the number of a patient suffering from the clonorchiasis. Increasing prevalence of GI diseases has boosted the market growth. According to the Survey of Digestive Health across Europe, 6% of total Europe population had some or other digestive diseases. Asia Pacific is the fastest growing region for the market owing to the presence of a huge patient population with GI diseases, continuously developing economies, and the presence of huge opportunity in the market.

On the other hand, the Middle East and Africa is holding the least share in the global clonorchiasis market due to the presence of poor economy, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key Players for Global Clonorchiasis Market

The key players in the global clonorchiasis market are 

• Pfizer (U.S)


• Bayer AG (Germany)


• Provet (Switzerland)


• Virbac (India)


• Cipla (India)


• Novartis AG (Switzerland)


• CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India)


• Merck & Co. Inc. (U.S.)


• Hoffmann-La Roche Ltd. (Switzerland)


• Abbott (U.S.)


• Arsanis Inc. (Austria)


• Novabiotics (U.K.)


• GlaxoSmithKline plc. (U.K.)


• Teva Pharmaceutical Industries Ltd (Taiwan)

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation

 Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers